Allergan (AGN) Releases Earnings Results, Beats Expectations By $0.21 EPS

Allergan (NYSE:AGN) posted its quarterly earnings data on Tuesday. The company reported $4.25 EPS for the quarter, beating the Zacks’ consensus estimate of $4.04 by $0.21, MarketWatch Earnings reports. Allergan had a negative net margin of 10.29% and a positive return on equity of 8.60%. The company had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.89 billion. During the same period in the prior year, the firm posted $4.15 EPS. The company’s quarterly revenue was down 3.0% on a year-over-year basis. Allergan updated its FY 2018 guidance to $16.20-16.60 EPS and its FY18 guidance to $16.20-16.60 EPS.

Shares of NYSE AGN opened at $160.67 on Wednesday. The firm has a market cap of $60.15 billion, a P/E ratio of 9.83, a P/E/G ratio of 1.34 and a beta of 1.19. Allergan has a 12-month low of $142.81 and a 12-month high of $197.00. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.85 and a current ratio of 1.00.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 14th. Investors of record on Tuesday, November 13th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.79%. The ex-dividend date of this dividend is Friday, November 9th. Allergan’s dividend payout ratio is presently 17.61%.



A number of equities research analysts have recently commented on the stock. Mizuho reaffirmed a “hold” rating and issued a $194.00 price objective on shares of Allergan in a research note on Monday, July 30th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $180.00 price objective on shares of Allergan in a research note on Friday, September 14th. Cowen set a $255.00 price objective on shares of Allergan and gave the company a “buy” rating in a research note on Tuesday. ValuEngine lowered shares of Allergan from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, Zacks Investment Research raised shares of Allergan from a “hold” rating to a “buy” rating and set a $197.00 price objective on the stock in a research note on Wednesday, July 11th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and eighteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $212.23.

In related news, Director Christopher J. Coughlin bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 6th. The shares were acquired at an average cost of $190.64 per share, with a total value of $1,906,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Joseph H. Boccuzi bought 900 shares of the business’s stock in a transaction that occurred on Thursday, August 30th. The shares were bought at an average cost of $190.59 per share, for a total transaction of $171,531.00. The disclosure for this purchase can be found here. 0.37% of the stock is owned by corporate insiders.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Read More: What is the 52-week high/low?

Earnings History for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply